CN-121978352-A - Application of ADAMTS-5 as biomarker of calcified aortic valve diseases

Abstract

The invention relates to the technical field of molecular markers, in particular to application of ADAMTS-5 as a biomarker for calcified aortic valve diseases. The invention discovers that ADAMTS-5 level in serum of CAVD patients is obviously reduced and the reduction of the severe CAVD group is particularly obvious through comparing ADAMTS-5 level in serum of a control group (patient without CAVD) and CAVD group patient, further develops a biomarker for CAVD diagnosis based on the significantly reduced ADAMTS-5 level, and then confirms that ADAMTS-5 is an independent predictor of CAVD and is not influenced by blood fat, renal function and other levels through verification. In addition, the subject work profile confirmed that ADAMTS-5 area under the curve (AUC) in CAVD diagnosis was significantly elevated to 0.799 (95% confidence interval: 0.750 to 0.848, P < 0.001), with good sensitivity and specificity.

Inventors

• An Guipeng
• GUO CHENGHU
• LIU XIAOLING
• ZHANG HAOWEI

Assignees

• 山东大学齐鲁医院

Dates

Publication Date

20260505

Application Date

20260408

Claims (10)

1. 1. Use of a biomarker or a substance that detects said biomarker in any of the following: (a1) Preparing a product for diagnosis or auxiliary diagnosis of calcified aortic valve diseases; (a2) Preparing a product for screening calcified aortic valve diseases; (a3) Preparing a product for predicting or assessing the risk of calcified aortic valve disease; (a4) Preparing a product for prognosis evaluation of calcified aortic valve diseases; wherein the biomarker is ADAMTS-5.
2. 2. The use according to claim 1, wherein the substance for detecting the biomarker is an agent for detecting ADAMTS-5 content.
3. 3. The use of claim 2, wherein the method of detecting the biomarker comprises an enzyme-linked immunosorbent assay, immunofluorescence, radioimmunoassay, co-immunoprecipitation, immunoblotting, high performance liquid chromatography, capillary gel electrophoresis, near infrared spectroscopy, mass spectrometry, immunochromatography, colloidal gold immunoassay, fluorescent immunochromatography, surface plasmon resonance, immuno-PCR or biotin-avidin.
4. 4. The use of claim 1, wherein the product comprises a kit, a protein chip, an immunochromatographic diagnostic test strip, a high-throughput sequencing platform, or a biosensor.
5. 5. A composition comprising an agent for detecting the level of ADAMTS-5.
6. 6. Use of the composition of claim 5 in any of the following: (b1) Preparing a product for diagnosis or auxiliary diagnosis of calcified aortic valve diseases; (b2) Preparing a product for screening calcified aortic valve diseases; (b3) Preparing a product for predicting or assessing the risk of calcified aortic valve disease; (b4) A product for prognosis evaluation of calcified aortic valve diseases is prepared.
7. 7. A kit comprising the composition of claim 5.
8. 8. Use of the kit of claim 7 in any of the following: (c1) Preparing a product for diagnosis or auxiliary diagnosis of calcified aortic valve diseases; (c2) Preparing a product for screening calcified aortic valve diseases; (c3) Preparing a product for predicting or assessing the risk of calcified aortic valve disease; (c4) A product for prognosis evaluation of calcified aortic valve diseases is prepared.
9. 9. The use according to claim 8, wherein the test sample of the kit is plasma.
10. 10. A device for diagnosis, assisted diagnosis, screening, risk prediction or prognosis of calcified aortic valve diseases, comprising reagents for detecting ADAMTS-5 content and a computer readable storage medium storing a computer program for causing a computer to perform the steps of: Diagnosis, auxiliary diagnosis, screening, risk prediction or prognosis of calcified aortic valve disease is performed according to ADAMTS-5 content.

Description

Application of ADAMTS-5 as biomarker of calcified aortic valve diseases Technical Field The invention relates to the technical field of molecular markers, in particular to application of ADAMTS-5 as a biomarker for calcified aortic valve diseases. Background Calcified aortic valve disease (calcific aortic VALVE DISEASE, CAVD) is an advanced senile disease with high morbidity and mortality, and the main pathophysiological change is the proliferation and calcification of aortic valve leaflet fibers, which leads to valve stiffening and causes hemodynamic changes, thus affecting cardiac function. CAVD is considered to be an age-related degenerative disease from the past perspective, which is the process of degenerating and hardening valve tissue with age. However, recent basic studies have shown that CAVD is an active progression of complex pathological changes involving endothelial injury, inflammatory cell infiltration, extracellular matrix remodeling, and valve stromal cell osteogenic differentiation. Cells in valve tissue mainly include valve endothelial cells, valve stromal cells, valve precursor cells, etc., and studies have demonstrated that calcium salt increase caused by osteogenic differentiation of valve stromal cells may be an important initiating factor for valve calcification. CAVD clinical symptoms vary according to the severity of the disease, and patients may not have obvious symptoms at the early stage of the disease, and symptoms such as dyspnea, chest pain, palpitation, syncope, dizziness, fatigue, edema and the like appear only after the disease progresses to the later stage, and the symptoms can be gradually aggravated with the severity of CAVD, and the quality of life is affected. Thus, early diagnosis and treatment is critical to CAVD. Disclosure of Invention To overcome the above problems, the present invention provides the use of ADAMTS-5 as a biomarker for calcified aortic valve disease. In order to achieve the technical purpose, the invention adopts the following technical scheme: In a first aspect of the invention there is provided the use of a biomarker or a substance for detecting said biomarker in any of the following: (a1) Preparing a product for diagnosis or auxiliary diagnosis of calcified aortic valve diseases; (a2) Preparing a product for screening calcified aortic valve diseases; (a3) Preparing a product for predicting or assessing the risk of calcified aortic valve disease; (a4) Preparing a product for prognosis evaluation of calcified aortic valve diseases; Wherein the biomarker is depolymerized protein-like metalloprotease thrombospondin 5 (ADAMTS-5). The amino acid of ADAMTS-5 is shown as SEQ ID NO. 1. In one or more embodiments, the agent that detects the biomarker is an agent that detects the level of ADAMTS-5. Preferably, the method of detecting the biomarker comprises an enzyme-linked immunosorbent assay, immunofluorescence method, radioimmunoassay, co-immunoprecipitation method, immunoblotting method, high performance liquid chromatography, capillary gel electrophoresis method, near infrared spectroscopy, mass spectrometry, immunochromatography, colloidal gold immunoassay, fluorescent immunochromatography, surface plasmon resonance, immuno-PCR or biotin-avidin technology. In one or more embodiments, the product includes a kit, a protein chip, an immunochromatographic diagnostic test strip, a high-throughput sequencing platform, or a biosensor. In a second aspect of the invention, a composition is provided that includes an agent for detecting ADAMTS-5 content. In a third aspect of the invention there is provided the use of a composition according to the second aspect in any of the following: (b1) Preparing a product for diagnosis or auxiliary diagnosis of calcified aortic valve diseases; (b2) Preparing a product for screening calcified aortic valve diseases; (b3) Preparing a product for predicting or assessing the risk of calcified aortic valve disease; (b4) A product for prognosis evaluation of calcified aortic valve diseases is prepared. In a fourth aspect of the invention there is provided a kit comprising a composition according to the second aspect. In a fifth aspect of the invention there is provided the use of a kit according to the fourth aspect in any of the following: (c1) Preparing a product for diagnosis or auxiliary diagnosis of calcified aortic valve diseases; (c2) Preparing a product for screening calcified aortic valve diseases; (c3) Preparing a product for predicting or assessing the risk of calcified aortic valve disease; (c4) A product for prognosis evaluation of calcified aortic valve diseases is prepared. In one or more embodiments, the test sample of the kit is plasma. In a sixth aspect of the present invention, there is provided an apparatus for diagnosis, assisted diagnosis, screening, risk prediction or prognosis of calcified aortic valve disease, comprising reagents for detecting ADAMTS-5 content and a computer readable storage medium stori